Is Elevance Health (ELV) Undervalued Following Its Recent Share Price Gains?

Elevance Health (ELV) continues to attract attention after recent share performance data showed a gain of 1% over the past day and 4% over the past week, compared with softer returns over the past month and past three months.

Recent trading hints at cooling momentum. The share price return is up 14.13% year to date and the latest close sits at US$404.31, yet the 3 year total shareholder return is down 6.28%. This suggests that Elevance Health has not rewarded longer term holders to the same extent.

Compare Elevance Health's mixed recent returns with other large caps by scanning our hand picked list of list of solid balance sheet and fundamentals (25 results) for ideas beyond a single healthcare insurer.

Recent gains at Elevance Health can signal either improving conviction in the underlying healthcare and pharmacy services platform or a swing in sentiment after a tougher three year stretch. How does the current price stack up against fundamentals?

Most Popular Narrative: 10% Undervalued

Against a most-followed fair value estimate of $451.38, Elevance Health trading at $404.31 prices in a discount that hinges on how well management controls healthcare costs and executes on its services platform.

Ongoing deployment of Elevance Health’s AI, analytics and digital platforms such as HealthOS and Sydney Health, including automated prior authorization and earlier visibility into medical cost trends, is expected to tighten medical cost management and support more stable net margins and earnings over time.

See why 113 investors see Elevance Health as 10% undervalued.

Result: Fair Value of $451.38 (UNDERVALUED)

Still, Elevance Health faces real pressure if Medicaid margins remain around the expected 2026 trough or if ACA and commercial medical costs keep climbing.

Find out about the key risks to this Elevance Health narrative.

Next Steps

If sentiment around Elevance Health feels mixed, that is a cue to check the numbers yourself and decide where you land. To see what investors are finding attractive right now, review the 4 key rewards.

Looking for more investment ideas beyond Elevance Health?

If Elevance Health has you thinking more broadly about where to put fresh capital, do not stop at a single ticker when smarter diversification is within reach.

• Target robust quality by reviewing our 29 high quality undervalued stocks that combine solid fundamentals with prices that do not fully reflect their financial strength.
• Lock in potential income streams by scanning a curated set of 8 dividend fortresses built around higher yields and resilient payouts.
• Protect against shocks by focusing on resilience first with a 31 resilient stocks with low risk scores designed to highlight businesses with sturdier risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com